Teva- Pharmaceutical Industries Profit Margin

Teva- Pharmaceutical Industries (TEVA) currently reports a profit margin of 9.02% as of March 2026. That compares with -7.73% in the prior-year period — up 216.6% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Teva- Pharmaceutical Industries's profit margin history and peer comparisons.

Teva- Pharmaceutical Industries's profit margin increased from -7.73% to 9.02% — a 216.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Teva- Pharmaceutical Industries's profit margin of 9.02% is lower than the Healthcare sector average of 15.58%. That is roughly 42.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Teva- Pharmaceutical Industries's current 9.02% should be judged against Healthcare norms (sector average: 15.58%) and against TEVA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 9.02%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Teva- Pharmaceutical Industries, and consider following TEVA for alerts when major investors trade the stock.